Navitoclax-piperazine

Overview

Navitoclax -piperazine (ABT-263-piperazine) is a Navitoclax ( HY-10087 ) analog and BCL-XL inhibitor. Navitoclax -piperazine is the ligand for target protein of PROTAC DT2216 ( HY-130604 ). Navitodax-pperaie and E3 ubiquitin ligase VHL ligand can be used to synthesize PROTAC DT2216 ( HY-130604 ).

Application

Products | Products > Disease Areas > Blood Disease | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Ligands for Target Protein for PROTAC | Products > Signaling Pathways > Bcl-2 Family

Product Information

• Catalog No.: HY-44432
• CAS No.: 2143096-93-7
• Molecular Formula: C47H56ClF3N6O5S3
• Molecular Weight: 973.63
• Purity: 99.73%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.08 mg/mL (2.14 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source